ICON’s Acquisition of MeDiNova Research
23 Mai 2019 - 3:00PM
Business Wire
Acquisition enhances ICON’s patient access
in Europe and Africa
ICON plc, (NASDAQ: ICLR) a global provider of drug
and device development and commercialisation services to
pharmaceutical, biotechnology, medical device industries, today
announced that it has acquired a majority shareholding in MeDiNova
Research, a site network with research sites in key markets in
Europe and Africa, and that it has the right to acquire the
remaining shares in the company by Quarter 3 2020.
The acquisition further enhances ICON’s patient recruitment
capabilities in EMEA and complements ICON’s existing site network
in the US, PMG Research.
Founded in 2000 and headquartered in Coventry, UK, MeDiNova
Research is a network of 33 active clinical research sites in the
UK, Spain, South Africa, Poland and Romania. The company has
experience operating a number of different site models, including
dedicated research sites, integrated research sites and working
closely with affiliate sites. MeDiNova Research has experience
across many therapeutic areas, with particular experience in
musculoskeletal, respiratory, cardiovascular, dermatology,
infectious disease, metabolic, general health and vaccine studies.
MeDiNova Research sites have a proprietary database of 400,000
patients who reside within easy reach of the sites. In addition,
MeDiNova Research has access to over 5 million potential study
patients via electronic medical records through strong healthcare
partnerships.
Kumar Muthalagappan OBE, Chief Executive Officer, MeDiNova
Research, said: “MeDiNova sites are focused on being high enrollers
coupled with high quality, to exceed our pharma clients’
expectations. Our solutions are based on reducing start up times,
early achievement of enrolment targets and high retention rates by
delivering an excellent patient experience. ICON provides MeDiNova
with a great opportunity for continued growth through scaling our
knowledge, infrastructures and healthcare relationships. The
MeDiNova-ICON combination will further enhance our highly
productive models to deliver best in class site performance for the
industry.”
Dr. Steve Cutler, Chief Executive Officer, ICON plc, said: “ICON
has a focused patient, site and data strategy which is helping us
to improve site identification, study placement and patient
recruitment and retention. A successful element of our strategy has
been our integrated PMG site network in the US and our ability to
grow alliances with third party sites and healthcare institutions
in the US and Europe. MeDiNova provides us with a platform to
further expand our site network in key EMEA markets and will help
us to recruit patients into studies faster. MeDiNova’s experience
in operating multiple site models and their strong therapeutic
expertise will greatly benefit our customers’ development
programmes.”
About MeDiNova Research
MeDiNova Research is a global network of quality research sites,
providing investigator based clinical research services to the
pharmaceutical and biotech industry. The company is a specialist in
Phase II-IV clinical studies in multiple therapeutic areas and has
outstanding global experience and expertise in the delivery of
quality clinical research. Headquartered in Coventry, United
Kingdom, MeDiNova Research currently operates from 33 active
clinical research sites in five countries and has approximately 160
employees.
Further information is available at www.medinovaresearch.com
About ICON plc
ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to the pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently, operates from 90 locations in 37 countries and has
approximately 13,920 employees.
Further information is available at www.iconplc.com/patients
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190523005402/en/
ICON MediaLucinda Sandon-AllumWeber Shandwick+44 (0)20
7067 0548lsandon-allum@webershandwick.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024